ABSTRACT
Patient-Centric Peptide-based Drug Design and Drug Delivery for Metabolic Disease
Peptide therapeutics have continued to be an innovative strategy for the development of biopharmaceutical pipelines. Several GLP-1 analogs made successes, even with few drawbacks, from twice-a-day (BID) injection to once-a-week (OW) treatment of Type 2 Diabetes. This presentation will describe the overcoming challenges for peptide optimization and patient-friendly peptide drug delivery technology including Medici Drug Delivery System™.
BIO
Ved Srivastava is Vice President of Peptide Chemistry at Intarcia Therapeutics. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline, USA; and in the leadership role with Amylin Pharmaceuticals, USA. Ved is President-Elect of the American Peptide Society. Ved has significantly participated in the development and commercialization of SymlinTM, ByettaTM, and BydeureonTM, first-in-class medicines for the treatment of diabetes. He is the Editor of three books: Peptide-based Drug Discovery, Comprehensive Medicinal Chemistry III - Biologics Medicine (Vol 6) and ‘Peptide 2015’. He earned a Ph.D. in organic chemistry from the University of Lucknow, India.
Patient-Centric Peptide-based Drug Design and Drug Delivery for Metabolic Disease
Peptide therapeutics have continued to be an innovative strategy for the development of biopharmaceutical pipelines. Several GLP-1 analogs made successes, even with few drawbacks, from twice-a-day (BID) injection to once-a-week (OW) treatment of Type 2 Diabetes. This presentation will describe the overcoming challenges for peptide optimization and patient-friendly peptide drug delivery technology including Medici Drug Delivery System™.
BIO
Ved Srivastava is Vice President of Peptide Chemistry at Intarcia Therapeutics. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline, USA; and in the leadership role with Amylin Pharmaceuticals, USA. Ved is President-Elect of the American Peptide Society. Ved has significantly participated in the development and commercialization of SymlinTM, ByettaTM, and BydeureonTM, first-in-class medicines for the treatment of diabetes. He is the Editor of three books: Peptide-based Drug Discovery, Comprehensive Medicinal Chemistry III - Biologics Medicine (Vol 6) and ‘Peptide 2015’. He earned a Ph.D. in organic chemistry from the University of Lucknow, India.